[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642846":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":7,"responsibleParty":13,"collaborators":7,"id":17,"slug":18,"hasResults":19,"nctId":20,"briefTitle":21,"officialTitle":21,"acronym":7,"eligibilityCriteria":22,"healthyVolunteers":19,"sex":23,"minAge":24,"maxAge":7,"enrollmentInfo":25,"targetDuration":7,"studyType":28,"phases":7,"briefSummary":29,"conditions":30,"keywords":7,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":7},{"fullName":5,"class":6},"Assiut University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Multi-omic spatial analysis","conduction of spatial multi-omic analyses comparing pediatric and adult liver tissues. This will include proteomic and transcriptomic mapping to understand how AAT accumulation and ductular reactions differ between the two forms.",{"type":14,"investigatorFullName":15,"investigatorTitle":16,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Yusuf Salah-eldin Amry Ahmad","Assistant Lecturer","100642846","natural-course-and-molecular-basis-of-alpha-1--antitrypsin-deficiency-associated-liver-disease-100642846",false,"NCT07639996","Natural Course and Molecular Basis of Alpha 1- Antitrypsin Deficiency-associated Liver Disease.","Inclusion Criteria:\n\n* Adult patients (≥18 years) with genetically confirmed alpha-1 antitrypsin deficiency (Pi\\*ZZ genotype).\n* Availability of longitudinal clinical follow-up data (minimum 5 years) within the AATD consortium.\n* At least one documented liver assessment including liver stiffness measurement (LSM) and serum-based fibrosis markers.\n* Availability of stored serum samples for proteomic analysis.\n* For translational analyses: availability of liver tissue samples (pediatric or adult) and\u002For induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells.\n\nExclusion Criteria:\n\n* Presence of other chronic liver diseases (e.g., viral hepatitis, autoimmune hepatitis) that may confound fibrosis assessment.\n* History of liver transplantation prior to study inclusion.\n* Incomplete clinical, laboratory, or follow-up data.\n* Poor-quality or insufficient biological samples for proteomic or molecular analyses.\n* Patients lost to follow-up or with unreliable longitudinal data","ALL","18 Years",{"count":26,"type":27},45,"ESTIMATED","OBSERVATIONAL","* To define the course of AATD-associated liver disease.\n* To use the obtained samples for biomedical research which includes:\n\n  1. Search for serum-based disease biomarkers and the associated molecular pathways.\n  2. Multi-omic spatial analysis of human AATD-LD.",[31],"Alpha 1-antitrypsin Deficiency (AATD)","NOT_YET_RECRUITING","2026-06-05",{"date":35,"type":36},"2026-06-10","ACTUAL",{"date":38,"type":27},"2026-10-01",{"date":40,"type":27},"2028-09-30",{"name":5,"class":6}]